Hsa_circ_0007534 as a blood-based marker for the diagnosis of colorectal cancer and its prognostic value

Background: Many studies have shown that differentially expressed circular RNA (circRNA) in plasma can serve as biomarkers in non-invasive detection of cancers during screening. However, the clinical significance of plasma circRNA in the diagnosis of colorectal cancer (CRC) is still not clear. Therefore, we examined expression of hsa_circ_0007534 in plasma to verify whether it can be utilized to diagnose and monitor CRC in routine clinical practice. Methods: 112 CRC patients and 46 healthy controls were recruited to participate in our study. The levels of hsa_circ_0007534 in plasma samples and tumor tissues were identified by real-time quantitative polymerase chain reaction (RT-qPCR). The diagnostic value was evaluated using receiver operating characteristics (ROC) curves and the area under the ROC curves (AUC). The Kaplan-Meier survival curve was used to evaluate whether the expression level of hsa_circ_0007534 was associated with overall survival rate. Results: Compared with the healthy control group, hsa_circ_0007534 expression was significantly increased in plasma from CRC patients. Increased hsa_circ_0007534 expression level in plasma was associated with progression of clinical classifications, metastatic phenotype, and poor differentiation in CRC patients. ROC analysis showed that hsa_circ_0007534 could distinguish CRC patients from healthy controls with high AUC (0.780), sensitivity (0.92) and specificity (0.522). Finally, high hsa_circ_0007534 expression was positively correlated with poor prognosis in CRC patients. Conclusion: All of the results suggest that hsa_circ_0007534 may be a potential cancer marker of patients with CRC and may associate with poor prognosis.